KYA1797K, one of derivatives of initial hits, was characterized as a compound that interacts with the RGS domain of axin and effectively suppresses the growth of CRC by the activation of GSK3β via enhancement of the β-catenin destruction complex [20]. Here, AXIN1 is linked to colorectal carcinoma.